Management of Traumatic Brain Injury: From Present to Future
ReviewHumansOther animals
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- What's known about managing traumatic brain injury: the inflammatory cascade that drives secondary injury, animal models, and existing and potential treatments for inflammation and behavioural deficits
What the authors reported
Secondary injury after traumatic brain injury is described as an inflammatory cascade with blood-brain barrier breakdown, oedema, immune cell infiltration and cytokine release, and the authors review neuroprotective strategies against it. The abstract does not mention palmitoylethanolamide findings or give numbers.
Limits of this study
A narrative review, not a trial. Salvatore Cuzzocrea holds patents with Epitech Group, which makes ultramicronised PEA; the authors say these are unrelated to the review.
Source
PubMed 32252390 · doi:10.3390/antiox9040297
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.